ᲚᲐᲚᲘ ᲥᲣᲠᲮᲣᲚᲘ
ლალი ქურხული
პულმონოლოგი
Dr. Lali Kurkhuli is a top-tier specialist in internal medicine and a member of both the Georgian and European Respiratory Associations. She has extensive experience working at the Tbilisi Medical Academy, medical diagnostic centers, and a cardiology center, with a particular focus on computer spirometry. Dr. Lali Kurkhuli has participated in numerous international congresses and research studies and is the author of seven medical articles. She is actively involved in clinical research in pulmonology, including studies on severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD). Currently, she serves as a consultant in a computer spirometry laboratory.
სამუშაო საათები:
Education
2005 - Tbilisi Georgia: Programme of continuous medical education “pneumonia”
2005 - Tbilisi, Georgia “Role of Gender in Health and Healthcare”
2004 - Moscow, Russia “Clinical Physiology of load and shortness of breath during lung diseases”
2001 - Tbilisi, Georgia. State Certificate “Internal Medicine”
1998 - Moscow, Russia. Qualification “Method of functional examination of lungs”
1979-1979 - Tbilisi, Georgia. Clinical residency “Internal Medicine”
1967-1974 - Tbilisi State Medical Institute. Diploma A-1 N145279
Work Experience
1973-1974 - Internship in Rustavi Metalurgic Factory Medical Division
1974-1977 - Chief Doctor in Patardzeuli hospital
1977-1979 - Tbilisi Doctors Training Institute, Clinical residency “Internal Medicine”
1970-1993 - Internal Medicine Doctor at the Clinic of Tbilisi Doctors Training Institute
1993-2003 - Tbilisi Medical Academy Clinic, Internal Medicine Doctor in the Department of Internal Medicine
1999-2012 - Medical Diagnostic Center, Functional Diagnostic Department, Doctor in the cabinet of Computer spyrography
since 2012 - L.T.D. Diagnostic Service, doctor in computer spyrography laboratory
since 2020 - Cito Medical Center
since 2022 - L.T.D Acad. G. Chapidze Emergency Cardiology Center , Computer spyrography laboratory, consultant
Clinical trials in Pulmonology
since 2025 - Sub-Investigator, An Open-Label Long-Term Phase III Extension Study to Assess the Long-Term Safety and Tolerability of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5)
since 2024 - Sub-Investigator, A randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-2)
since 2023 - Sub-Investigator, A 52-week, randomized, double-blind, placebo-controlled, parallel-group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
2014-2015 - Sub-investigator, Randomized, double-blind, multicenter study of intravenous and oral administration of solitromitsinis (CEM-101)comparing its efficacy and safety with intravenous and then oral use of moxifloxacin in the adult outpatient treatment from pneumonia of bacterial origin "CE01-301
2014-2015 - Sub-investigator, "Multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of Pulmaquin®, in subjects with not-cistic fribrosis bronchiectasis with chronic lung infections caused by Pseudomonas aureginosa, 28-day open-label, extension period (ORBIT-4) (ARD-3150-1202)
2010-2013 - Sub-investigator, Study of anti-cholinergic agent in COPD provided with two different inhalation devices.